| ²é¿´: 432 | »Ø¸´: 1 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
liboyggÒø³æ (СÓÐÃûÆø)
|
[ÇóÖú]
ÇóÒ»¶ÎÂÛÎÄ·Ò룬Òò±¾ÈËÊÇѧ¶íÓïµÄ£¬Ó¦¸Ãͦ¼òµ¥µÄ£¬Ð»Ð»
|
||
|
How important coadministration of antiplatelet agents is in the pathogenesis of some of these hemorrhagic events is unclear in the context of uremic platelet dysfunction. Antiplatelet agents were administered to 7 of our 10 patients and 1 of the 5 cases described. However, their use would not explain the prolonged APTT seen in 7 of our 10 cases. Four of our patients were on the maintenance hemodialysis program; although the onset of bleeding was on nondialysis days in all patients and the quoted APTTs were 48 hours after hemodialysis, the possible contribution of heparin during dialysis treatment remains unclear. Finally, in our case series, 7 of 10 patients had end-stage renal disease (ESRD), but 1 patient had a CrCl of 30 mL/min (0.50 mL/s) and still experienced a major hemorrhagic event (Fig1). Although there was an overlap with warfarin therapy, he had only been administered 2 doses,and his international normalized ratio was 2.4. LMWHs are derived from standard UFH through controlled chemical or enzymatic degradation, resulting in heterogeneous molecules with individual pharmacological properties. Each commercial product is considered by theWorld Health Organization as a distinct and noninterchangeable drug. There are important differences between LMWHs and UFH, but the clinical relevance of their differences in terms of effectiveness or safety remains unclear. Hence, LMWHs have a reduced ability to catalyze the inhibition of thrombin (IIa), whereas they retain the ability to inhibit Xa activity. The reduced binding of LMWH to plasma proteins and cells (including platelets, endothelial cells, and macrophages) contributes to its more predictable dose response and longer plasma half-life. LMWHs are eliminated primarily by the kidney through glomerular filtration in comparison to UFH, in which renal clearance becomes an important route of elimination only at greater concentrations. |
» ²ÂÄãϲ»¶
һ־Ը³¶«´óѧ071000ÉúÎïѧѧ˶³õÊÔ·ÖÊý276Çóµ÷¼Á
ÒѾÓÐ15È˻ظ´
308Çóµ÷¼Á
ÒѾÓÐ17È˻ظ´
Ò»Ö¾Ô¸0807 ÊýÒ»Ó¢Ò» 313 ÓÐûÓжþÂÖµ÷¼Á
ÒѾÓÐ12È˻ظ´
²ÄÁϵ÷¼Á
ÒѾÓÐ5È˻ظ´
289 ·Ö105500ҩѧר˶Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
¿¼Ñе÷¼Á-²ÄÁÏÀà-284
ÒѾÓÐ21È˻ظ´
314Çóµ÷¼Á
ÒѾÓÐ11È˻ظ´
0703µ÷¼Á
ÒѾÓÐ19È˻ظ´
Ò»Ö¾Ô¸±±¾©2£¬²ÄÁÏÓ뻯¹¤308Çóµ÷¼Á
ÒѾÓÐ18È˻ظ´
086004 Çóµ÷¼Á 309
ÒѾÓÐ3È˻ظ´
nwsuafliu
ľ³æ (ÖøÃûдÊÖ)
- ·ÒëEPI: 144
- Ó¦Öú: 42 (СѧÉú)
- ½ð±Ò: 2406.9
- É¢½ð: 1449
- ºì»¨: 18
- Ìû×Ó: 1437
- ÔÚÏß: 315.6Сʱ
- ³æºÅ: 136928
- ×¢²á: 2005-12-17
- רҵ: ×÷Îï·Ö×ÓÓýÖÖ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
°®ÓëÓêÏÂ: ½ð±Ò+1 2013-01-01 21:31:22
liboygg: ½ð±Ò+50, ·ÒëEPI+1, ¡ïÓаïÖú, ÌõÀí»¹ÊDz»ÔõôÇå³þ 2013-01-03 19:35:12
°®ÓëÓêÏÂ: ½ð±Ò+1 2013-01-01 21:31:22
liboygg: ½ð±Ò+50, ·ÒëEPI+1, ¡ïÓаïÖú, ÌõÀí»¹ÊDz»ÔõôÇå³þ 2013-01-03 19:35:12
| ÔÚÄò¶¾ÐÔѪС°å¹¦ÄÜÒì³£ÏÂ,¶àÖÖ¿¹ÑªÐ¡°åÒ©ÎïÁªÓöÔһЩʧѪʼþµÄ²¡Àí½ø³ÌÓкÎÖØÒªÒâÒå,Éв»Çå³þ¡£¿¹ÑªÐ¡°åÒ©ÎïÓÃÓÚËùÊöµÄ10¸ö²¡ÈËÖеÄ7¸ö£¬ÒÔ¼°5¸ö²¡ÀýÖеÄÒ»¸ö¡£È»¶ø£¬ÕâЩҩÎïµÄʹÓò»ÄܽâÊÍÎÒÃÇÔÚ10¸ö²¡ÀýÖеÄ7¸öÖй۲쵽µÄAPTTµÄÑÓ³¤¡£ÎÒÃǵÄ4¸ö²¡ÈËÔøÔÚ½ÓÊÜά³ÖÐÔѪҺ͸Îö£»ËäÈ»ËùÓв¡ÈËÉøÑªµÄ¿ªÊ¼ÊÇÔÚ·Ç͸ÎöÈÕ£¬ÇÒ²ÉÓõÄAPTTsÖµÊÇ͸Îö48СʱºóµÄÖµ£¬Í¸ÎöÖÎÁÆÖиÎËØµÄ¿ÉÄܹ±Ï×Éв»Çå³þ¡£×îºó£¬ÔÚÎÒÃǵIJ¡ÀýϵÁÐÀ10¸ö²¡ÈËÖеÄ7¸ö»¼ÓÐÖÕÄ©ÆÚÉöÔಡ£¬µ«ÊÇÆäÖÐ1¸ö²¡È˵ÄCrClֵΪ30 mL/min (0.50 mL/s)£¬ÈÔÈ»¾ÀúÁË´ó³öѪʼþ£¨Í¼1£©¡£¾¡¹ÜºÍ»ª·¨ÁÖ¿¹ÄýÖÎÁÆ´æÔÚÒ»¶¨µÄÖØµþ£¬¸Ã²¡È˽öʹÓÃÁË2¼ÁÁ¿£¬ËûµÄ¹ú¼Ê±ê×¼»¯±ÈÂÊΪ2.4¡£LMWHsÔ´×Ô»¯Ñ§½µ½â»òø½µ½âµÄ±ê×¼UFH£¬µ¼ÖÂÒìÖÊ·Ö×Ó¾ßÓи÷×ÔµÄÒ©Ñ§ÌØÐÔ¡£Ã¿¸öÉÌÒµ²úÆ·¶¼±»ÊÀ½çÎÀÉú×éÖ¯ÈÏΪÊǶÀÌØµÄ²»¿ÉÏà»¥Ìæ»»µÄÒ©Îï¡£LMWHs ºÍ UFHÓÐ×ÅÖØÒªÇø±ð£¬µ«ÊǾÍÁÆÐ§»ò°²È«ÐÔ¶øÑÔ£¬ËüÃÇÕâÐ©Çø±ðµÄÁÙ´²Ïà¹ØÐÔÈÔ²»Çå³þ¡£Òò´Ë£¬ LMWHsÒÖÖÆÄýѪø (IIa)µÄ´ß»¯ÄÜÁ¦½µµÍÁË£¬µ«ÊÇÈÔÈ»±£³ÖÆäÒÖÖÆXa»îÐÔµÄÄÜÁ¦¡£LMWHºÍѪ½¬µ°°×¼°Ï¸°û£¨°üÀ¨ÑªÐ¡°å¡¢ÄÚÆ¤Ï¸°ûºÍ¾ÞÊÉϸ°û£©µÄ½áºÏÁ¦½µµÍ£¬Æä¼ÁÁ¿·´Ó¦¾ßÓиüºÃµÄ¿ÉÔ¤²âÐÔ£¬²¢ÄÜÑÓ³¤Ñª½¬°ëË¥ÆÚ¡£ÓëUFH Ïà±È£¬LMWHsÖ÷ÒªÓÉÉöͨ¹ýÉöСÇòÂ˹ýÈ¥³ý£¬UFHÖ»ÓÐÔڽϸßŨ¶Èʱ£¬ÉöÇå³ý²ÅÊÇÒ»ÌõÖØÒªµÄÇå³ý;¾¶¡£ |

2Â¥2013-01-01 21:03:41













»Ø¸´´ËÂ¥